10.2 HER2-Targeted Monoclonal Antibodies, Antibody-Drug Conjugates & Kinase Inhibitors

Targeted therapies directed against the human epidermal growth factor receptor 2 (HER2) have fundamentally reshaped the clinical trajectory of HER2-overexpressing breast cancer, transforming an aggressive biological subtype into one of the most successfully managed malignancies in clinical oncology.

HER2 Molecular Pathway and Biology of Receptor Overexpression

The human epidermal growth factor receptor 2 (HER2, encoded by the ERBB2 proto-oncogene on chromosome 17q12) is a 185-kDa transmembrane receptor tyrosine kinase belonging to the EGFR/ErbB family. The receptor consists of an extracellular ligand-binding domain (composed of subdomains I through IV), a lipophilic transmembrane segment, and an intracellular cytoplasmic tyrosine kinase catalytic domain.

Unlike other ErbB family members (EGFR/ErbB1, HER3/ErbB3, HER4/ErbB4), HER2 has no known high-affinity endogenous ligand; it exists in a constitutively "open" or active conformation, functioning as the preferred dimerization partner for all other ligand-activated ErbB receptors. Heterodimerization—particularly between HER2 and HER3—represents the most potent oncogenic signaling unit in human oncology. When a ligand such as neuregulin binds HER3, HER2-HER3 heterodimerization triggers trans-autophosphorylation of intracellular tyrosine residues. This autophosphorylation recruits adaptor proteins that hyperactivate two primary downstream cascades:

1. PI3K / Akt / mTOR Pathway: Drives malignant cell survival, inhibition of pro-apoptotic Bcl-2 family members, metabolic reprogramming, and resistance to cytotoxic therapy.
2. Ras / Raf / MEK / ERK (MAPK) Pathway: Stimulates gene transcription driving rapid cellular proliferation, angiogenesis via vascular endothelial growth factor (VEGF), and metastatic invasion.

HER2 gene amplification or protein overexpression occurs in approximately 15% to 20% of invasive breast carcinomas. Historically, HER2-positive breast cancer was characterized by aggressive tumor biology, accelerated clinical progression, early visceral and central nervous system (CNS) metastases, resistance to conventional hormonal therapies, and poor overall survival. Modern targeted therapeutics neutralize this oncogenic driver via monoclonal antibodies, engineered cytotoxic antibody conjugates, and intracellular kinase inhibitors.

---

Monoclonal Antibodies: Trastuzumab and Pertuzumab

Humanized monoclonal antibodies targeting distinct extracellular epitopes of the HER2 receptor serve as the foundational backbone of systemic therapy in both early-stage and metastatic HER2-positive disease.

Trastuzumab (Herceptin)

Trastuzumab is a recombinant humanized IgG1 kappa monoclonal antibody that binds with high affinity to subdomain IV of the extracellular domain of HER2, immediately adjacent to the cell membrane.

Mechanisms of Action:

• Inhibition of Downstream Signaling: Trastuzumab sterically hinders HER2 cleavage by metalloproteinases, preventing the formation of p95HER2, a truncated, constitutively active intracellular kinase fragment. It suppresses PI3K/Akt activation, downregulates cyclin D1, promotes p27Kip1 nuclear accumulation, and arrests cells in G1 phase.
• Antibody-Dependent Cellular Cytotoxicity (ADCC): The human IgG1 Fc domain of trastuzumab binds CD16 (Fc-gamma-RIII) receptors on host immune effector cells, predominantly natural killer (NK) cells and macrophages. This engagement triggers cytotoxic degranulation (perforin and granzymes) and phagocytosis, destroying HER2-overexpressing tumor cells via innate immune mechanisms.
• Inhibition of Angiogenesis: Trastuzumab downregulates pro-angiogenic factors, including VEGF and basic fibroblast growth factor (bFGF).

Landmark Adjuvant Clinical Trials: Major landmark randomized trials—including HERA (Herceptin Adjuvant), NSABP B-31, NCCTG N9831, and BCIRG 006—demonstrated that adding 1 year of adjuvant trastuzumab to standard chemotherapy reduces the risk of breast cancer recurrence by approximately 50% and reduces mortality by 30% to 37%. Standard adjuvant administration delivers an intravenous loading dose of 8 mg/kg followed by 6 mg/kg every 3 weeks (or weekly dosing of 4 mg/kg load followed by 2 mg/kg), or a fixed-dose subcutaneous formulation (600 mg every 3 weeks), completed for a total duration of 52 weeks (1 year). Prolonging adjuvant therapy to 2 years demonstrated no additional survival benefit, while truncating therapy to 6 months yielded inferior disease-free survival in non-inferiority trials (PHARE).

Pertuzumab (Perjeta)

Pertuzumab is a recombinant humanized IgG1 monoclonal antibody that binds to subdomain II (the dimerization arm) of the extracellular domain of HER2.

Complementary Dual Blockade: While trastuzumab binds subdomain IV, pertuzumab sterically blocks the critical dimerization domain required for HER2 to partner with HER3 and other ErbB receptors. Combining trastuzumab and pertuzumab achieves comprehensive "dual HER2 blockade": pertuzumab shuts down HER2-HER3 heterodimerization and ligand-activated signaling, while trastuzumab inhibits homodimerization, suppresses receptor shedding, and activates potent ADCC.

Landmark Clinical Evidence:

• CLEOPATRA Trial (Metastatic Setting): First-line metastatic HER2-positive breast cancer randomized to docetaxel plus trastuzumab with or without pertuzumab. Adding pertuzumab extended median progression-free survival by 6.3 months and prolonged median overall survival by an unprecedented 15.7 months (56.5 months vs 40.8 months).
• NeoSphere and TRYPHAENA Trials (Neoadjuvant Setting): Dual blockade with pertuzumab, trastuzumab, and taxane-based chemotherapy doubled pathologic complete response (pCR) rates compared to trastuzumab plus chemotherapy, establishing dual blockade as the standard neoadjuvant regimen for tumors ≥ 2 cm (T2) or node-positive disease.
• APHINITY Trial (Adjuvant Setting): Demonstrated that adding 1 year of adjuvant pertuzumab to chemotherapy and trastuzumab produces a statistically significant improvement in invasive disease-free survival in high-risk patients with node-positive early breast cancer.

---

Trastuzumab Cardiotoxicity Surveillance and Holding Algorithms

Cardiac dysfunction represents the most clinically significant adverse effect associated with trastuzumab and HER2-targeted monoclonal antibodies.

Pathophysiological Distinction: Type I vs Type II Cardiotoxicity

Cardiac toxicity from cancer therapeutics is classified into two distinct biological categories:

• Type I (Anthracycline-Induced): Dose-dependent, cumulative, progressive myocardial damage caused by reactive oxygen species, topoisomerase II-beta inhibition, and microvascular dropout. Histopathologically characterized by cardiomyocyte vacuolization, myofibrillar loss, and necrosis; injury is permanent and irreversible.
• Type II (Trastuzumab-Induced): Non-dose-dependent, non-cumulative, functional myocardial stunning. HER2 signaling via ErbB2-ErbB4 neuregulin pathways is essential for adult cardiomyocyte stress survival, mitochondrial integrity, and response to hemodynamic overload. Trastuzumab disrupts this cardioprotective signaling, leading to contractile dysfunction without structural cardiomyocyte necrosis. Consequently, Type II cardiotoxicity is largely reversible upon drug discontinuation and guideline-directed medical therapy.

The risk of cardiotoxicity increases dramatically when trastuzumab is administered concurrently with anthracyclines (in the pivotal metastatic trial, 27% of patients receiving concurrent trastuzumab and an anthracycline developed cardiac dysfunction, 16% of them NYHA class III or IV). Therefore, concurrent anthracycline and trastuzumab administration is strictly avoided; modern regimens sequence anthracyclines prior to trastuzumab (AC followed by TH) or omit anthracyclines entirely using non-anthracycline platinum-based regimens (TCH: docetaxel, carboplatin, trastuzumab).

Cardiac Monitoring Surveillance Schedules

• Baseline Assessment: Prior to initiating trastuzumab, a baseline evaluation of left ventricular ejection fraction (LVEF) via 2D echocardiogram with strain or multi-gated acquisition (MUGA) scan is mandatory. Treatment should not be initiated if baseline LVEF is < 50%.
• Serial Surveillance: LVEF must be reassessed every 3 months throughout active therapy, and at 6 to 12 months following completion of adjuvant treatment.

Standard Clinical Holding and Resumption Algorithm

When surveillance imaging demonstrates an asymptomatic decline in LVEF, standardized holding criteria must be applied:

1. Holding Parameters:
   • Withhold trastuzumab if LVEF drops ≥ 16% from baseline, OR
   • Withhold trastuzumab if LVEF falls below the institutional lower limit of normal (typically < 50%) AND exhibits an absolute drop of ≥ 10% from baseline.
2. Clinical Management During Hold:
   • Perform prompt clinical evaluation for signs and symptoms of congestive heart failure (dyspnea on exertion, orthopnea, paroxysmal nocturnal dyspnea, peripheral lower extremity edema, jugular venous distension).
   • Refer to cardio-oncology; initiate cardioprotective medical therapy with angiotensin-converting enzyme (ACE) inhibitors (e.g., lisinopril) or angiotensin receptor blockers (ARBs) and beta-blockers (e.g., carvedilol, metoprolol succinate).
   • Repeat echocardiographic assessment of LVEF in 3 to 4 weeks.
3. Resumption Criteria:
   • Trastuzumab may be resumed if LVEF recovers to within normal limits and the absolute decrease from baseline is ≤ 15%.
   • Per the trastuzumab label, permanently discontinue for a persistent (more than 8 weeks) LVEF decline or when trastuzumab has been held for cardiomyopathy on more than 3 occasions; symptomatic heart failure is managed with cardiology and usually ends treatment.

---

Antibody-Drug Conjugates (ADCs): Mechanism and Key Agents

Antibody-drug conjugates (ADCs) are complex targeted biopharmaceuticals designed to deliver high-potency cytotoxic payloads directly into antigen-bearing malignant cells, thereby maximizing tumoricidal eradication while minimizing systemic off-target toxicities. An ADC comprises three fundamental structural components:

1. Target-Specific Monoclonal Antibody: Directs the molecule to tumor-associated cell-surface antigens.
2. Potent Cytotoxic Payload: An antineoplastic agent (e.g., tubulin inhibitor or topoisomerase I inhibitor) too toxic for systemic intravenous administration alone.
3. Chemical Linker: Covalently joins the payload to the antibody; designed to be stable in systemic circulation and selectively cleaved or degraded inside the malignant cell.

Ado-Trastuzumab Emtansine (T-DM1 / Kadcyla)

T-DM1 consists of trastuzumab covalently bound to DM1 (a synthetic maytansine derivative that inhibits tubulin polymerization and microtubule assembly) via a stable, non-cleavable thioether linker (MCC). T-DM1 has a drug-to-antibody ratio (DAR) of approximately 3.5:1.

• Mechanism of Action: T-DM1 binds subdomain IV of HER2, undergoes receptor-mediated endocytosis, and is trafficked to lysosomes. Lysosomal proteases degrade the antibody backbone, releasing lysine-MCC-DM1 into the cytoplasm. DM1 binds tubulin, disrupting mitotic spindle architecture and inducing mitotic catastrophe and apoptotic cell death. Because the non-cleavable linker remains attached to the charged lysine residue, the active payload cannot diffuse across membranes into adjacent cells, confining cytotoxicity strictly to HER2-overexpressing cells.
• Landmark KATHERINE Trial (Adjuvant Residual Disease): Patients with HER2-positive early breast cancer who have residual invasive disease in the breast or axillary lymph nodes following neoadjuvant taxane- and trastuzumab-based chemotherapy were randomized to 14 cycles of adjuvant T-DM1 (3.6 mg/kg IV every 3 weeks) versus standard adjuvant trastuzumab. T-DM1 produced a 50% relative reduction in the risk of invasive disease recurrence or death (3-year invasive DFS: 88.3% vs 77.0%), establishing adjuvant T-DM1 as the standard of care for post-neoadjuvant residual disease.
• T-DM1 Toxicities and Nursing Care:
  • Thrombocytopenia: Dose-limiting toxicity; platelet nadir typically occurs on days 8 through 10, recovering prior to the next cycle. Platelets must be monitored prior to every dose. Dose reduction required for Grade 3/4 thrombocytopenia (< 50,000/mcL).
  • Hepatotoxicity: Transaminitis (elevated AST/ALT) and hyperbilirubinemia; rare cases of nodular regenerative hyperplasia (NRH) of the liver leading to non-cirrhotic portal hypertension. Regular liver function testing is mandated.
  • Peripheral Neuropathy: Sensory neuropathy resulting from tubulin inhibition; assess for numbness, tingling, or fine motor impairment.

Trastuzumab Deruxtecan (T-DXd / Enhertu)

Trastuzumab deruxtecan represents a next-generation ADC engineered with three distinct architectural advantages:

• Novel Payload: Deruxtecan (DXd) is an exatecan derivative and potent DNA topoisomerase I inhibitor, approximately 10 times more potent than SN-38.
• High Drug-to-Antibody Ratio (DAR): Utilizes an engineered, conditionally cleavable tetrapeptide linker that achieves a high DAR of 8:1 (eight deruxtecan molecules per antibody) without compromising systemic stability or pharmacokinetics.
• Membrane-Permeable Payload and Bystander Antitumor Effect: Once cleaved by lysosomal cathepsins in target cells, released deruxtecan is neutral and highly membrane-permeable. It freely diffuses out of the primary target cell into the surrounding tumor microenvironment, destroying adjacent heterogeneous tumor cells regardless of whether they express HER2.

Landmark Clinical Trials:

• DESTINY-Breast03: Second-line metastatic HER2-positive breast cancer randomized to T-DXd (5.4 mg/kg IV every 3 weeks) versus T-DM1. T-DXd demonstrated an unprecedented 72% reduction in the risk of disease progression or death, establishing T-DXd as the preferred second-line standard of care.
• DESTINY-Breast04: Evaluated T-DXd in patients with "HER2-low" metastatic breast cancer (defined as IHC 1+ or IHC 2+ with negative in situ hybridization [ISH-]), previously categorized and treated as HER2-negative. T-DXd produced statistically significant and clinically dramatic improvements in both progression-free survival (median 9.9 vs 5.1 months) and overall survival (median 23.4 vs 16.8 months) compared to physician's choice chemotherapy. This landmark trial redefined breast cancer classification, opening targeted therapy to up to 60% of patients previously deemed HER2-negative.
• DESTINY-Breast06: Extended benefit to HR-positive, chemotherapy-naive metastatic disease that is HER2-low or HER2-ultralow (IHC 0 with faint staining in 10% or fewer of cells) after endocrine therapy, leading to FDA approval in January 2025.

Critical Toxicity: Interstitial Lung Disease (ILD) / Pneumonitis ILD/pneumonitis is a serious, potentially life-threatening class toxicity occurring in 10% to 15% of patients treated with T-DXd.

• Clinical Surveillance: The oncology nurse must screen patients before every infusion for emergent respiratory symptoms, including dry cough, progressive dyspnea on exertion, low-grade fever, chest tightness, or declining pulse oximetry.
• Diagnostic Evaluation: Any suspected respiratory symptom warrants immediate dose hold and high-resolution computed tomography (HRCT) of the chest, alongside infectious workup.
• Management Algorithm:
  • Grade 1 (Asymptomatic, Radiographic Changes Only): Withhold T-DXd until resolution to Grade 0 and consider corticosteroids (at least 0.5 mg/kg/day of prednisolone or equivalent). If it resolves within 28 days, resume at the same dose; if it takes longer than 28 days, reduce by one dose level.
  • Grade 2, 3, or 4 (Symptomatic, Mild/Moderate/Severe Hypoxia): Permanently discontinue T-DXd immediately. Promptly initiate systemic corticosteroids (prednisone or methylprednisolone 1 to 2 mg/kg/day) and maintain for at least 14 days, followed by a gradual taper over at least 4 weeks. Hospital admission and pulmonology consultation are mandatory for Grade 3 or 4 events.
• Additional T-DXd Toxicities: Nausea and vomiting (NCCN classifies T-DXd as highly emetogenic, so three- or four-drug prophylaxis with an NK1 antagonist, a 5-HT3 antagonist, dexamethasone, and often olanzapine is used), myelosuppression (neutropenia, anemia), and alopecia.

---

Small Molecule Tyrosine Kinase Inhibitors: Tucatinib, Neratinib, and Lapatinib

Small molecule tyrosine kinase inhibitors (TKIs) are orally bioavailable synthetic compounds that penetrate the cellular plasma membrane to bind directly to the intracellular ATP-binding catalytic cleft of ErbB receptor tyrosine kinases. Because of their low molecular weight, TKIs possess the unique capability to cross the blood-brain barrier.

Tucatinib (Tukysa)

Tucatinib is an orally bioavailable, highly selective HER2 tyrosine kinase inhibitor that exerts minimal inhibitory activity against EGFR (HER1). This selective binding profile preserves normal epidermal EGFR signaling, dramatically reducing the severe diarrhea and acneiform skin rashes characteristic of first-generation dual inhibitors.

• HER2CLIMB Landmark Trial: Randomized patients with advanced or metastatic HER2-positive breast cancer previously treated with trastuzumab, pertuzumab, and T-DM1 to tucatinib (300 mg orally twice daily) or placebo, combined with trastuzumab and capecitabine. Critically, HER2CLIMB enrolled patients with active, progressive, or untreated brain metastases. Tucatinib demonstrated a statistically significant 46% reduction in the risk of disease progression or death in the overall cohort, and a 52% reduction in risk of progression or death in patients with active brain metastases, alongside a profound overall survival advantage.
• Adverse Effects: Mild diarrhea (manageable with loperamide), elevated hepatic aminotransferases (AST/ALT), fatigue, and capecitabine-associated palmar-plantar erythrodysesthesia (hand-foot syndrome).

Neratinib (Nerlynx)

Neratinib is an irreversible pan-HER inhibitor that covalently binds the ATP-binding pocket of HER1 (EGFR), HER2, and HER4.

• ExteNET Landmark Trial: Evaluated 1 year of extended adjuvant neratinib (240 mg orally once daily) following completion of 1 year of adjuvant trastuzumab in patients with early-stage HER2-positive breast cancer. The trial demonstrated a significant reduction in invasive disease recurrence, with the greatest benefit observed in patients with co-existing hormone receptor-positive disease (HR+/HER2+).
• Severe Diarrhea Toxicity and Mandatory Prophylaxis: In the ExteNET trial, Grade 3 diarrhea occurred in 40% of patients in the absence of prophylaxis, typically within the first 48 to 72 hours of treatment. Consequently, mandatory antidiarrheal prophylaxis is required:
  • Initiate high-dose scheduled loperamide with the very first dose of neratinib: 4 mg three times daily for weeks 1 through 2, followed by 4 mg twice daily for weeks 3 through 8, and 4 mg as needed thereafter.
  • Alternatively, implement a structured 2-week dose-escalation schedule (starting neratinib at 120 mg daily, increasing to 160 mg daily at week 2, and reaching 240 mg daily at week 3) to significantly improve gastrointestinal tolerability.

Lapatinib (Tykerb)

Lapatinib is an orally active, reversible dual inhibitor of both EGFR and HER2. Historically utilized in combination with capecitabine in metastatic disease progressing on trastuzumab, its clinical utilization has largely been superseded by tucatinib and next-generation ADCs due to its prominent EGFR-mediated toxicities (frequent Grade 3 diarrhea, extensive acneiform rash).

---

Bispecific Antibodies

The CBCN outline names bispecific antibodies among systemic therapies. A bispecific antibody binds two different targets or two epitopes at once. Zanidatamab binds two separate HER2 epitopes (the regions targeted by trastuzumab and pertuzumab) on one molecule; it received FDA accelerated approval in November 2024 for previously treated HER2-positive biliary tract cancer and is being studied in HER2-positive breast cancer. Other bispecifics in breast cancer trials pair HER2 with HER3 or engage T cells. Nursing care mirrors other HER2 antibodies: infusion-reaction precautions, diarrhea management, LVEF monitoring, and embryo-fetal toxicity counseling. Expect conceptual questions (what "bispecific" means and which class toxicities to monitor) rather than dosing.

---

HER2-Targeted Agents Comparison

---

Nursing Practice Considerations: Toxicities Management and Patient Education

Certified breast care nurses coordinate complex multidisciplinary care, perform toxicities monitoring, and provide tailored patient education across all phases of HER2-targeted therapy.

Infusion Reactions and Hypersensitivity Management

Infusion-related reactions (IRRs) occur most frequently during the initial loading dose of trastuzumab or pertuzumab (manifesting as fever, chills, rigors, flushing, bronchospasm, or urticaria).

• Nursing Interventions: Have emergency medications (diphenhydramine, acetaminophen, famotidine, hydrocortisone, epinephrine) immediately available. Ensure the initial infusion runs over 90 minutes. If moderate rigors or dyspnea occur, interrupt the infusion immediately, administer intravenous antihistamines and corticosteroids, and re-initiate at half the infusion rate once symptoms abate. Subsequent maintenance infusions can be administered over 30 minutes if initial doses are well tolerated.

Distinguishing ADC Safety Profiles: T-DM1 vs T-DXd

Nurses must maintain high vigilance to prevent medication errors between distinct antibody-drug conjugates:

• T-DM1 Safety Focus: Primarily hematologic and hepatic. Ensure platelet counts are ≥ 50,000/mcL before treatment; monitor for spontaneous bruising, epistaxis, or bleeding gums. Check transaminases and total bilirubin prior to every cycle.
• T-DXd Safety Focus: Primarily pulmonary and gastrointestinal. Educate patients that any new cough or breathlessness is a medical emergency requiring immediate clinical evaluation. Provide highly emetogenic-level antiemetic prophylaxis (NK1 antagonist, 5-HT3 antagonist, and dexamethasone, often with olanzapine) prior to infusion and prescribe breakthrough antiemetics (prochlorperazine, olanzapine) for home use.

Patient Education on CNS Metastases and TKI Therapy

Up to 30% to 50% of patients with metastatic HER2-positive breast cancer develop brain metastases during their disease course. Nurses must educate patients on neurological warning signs, including persistent morning headaches, new-onset nausea or vomiting, focal weakness, numbness, gait instability, cognitive changes, or visual field deficits. Patients initiated on tucatinib or neratinib must receive thorough instruction on medication compliance, oral hydration, dietary modifications, and immediate reporting of uncontrolled watery stools.